Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Hemoglobin A1c Unrelated to Diabetic Foot Ulcer Healing

By HospiMedica International staff writers
Posted on 10 May 2018
A new study concludes that there is no clinically meaningful association between hemoglobin A1c (HbA1c) levels and wound healing in patients with diabetic foot ulcers (DFUs).

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) conducted a retrospective study involving 270 patients with a total of 584 DFUs treated at JHU during a 4.7-year period. More...
The analysis assessed incidence of wound healing at any follow-up time, in relation to categories of baseline HbA1c and the incidence of long-term (over 90 days) wound healing. Tertiles of nadir HbA1c change and mean HbA1c change from baseline were measured, adjusting for potential confounders.

The results revealed that baseline HbA1c was not associated with wound healing. While a nadir change of 0.09 to 2.4 (third tertile) was positively associated with long-term wound healing in study participants with baseline HbA1c lower than 7.5%, no such association was seen with mean HbA1c change. Neither nadir HbA1c change nor mean HbA1c change were associated with long-term wound healing in participants with a baseline HbA1c higher than 7.5%. The study was published on April 16, 2018, in Diabetes Care.

“There does not appear to be a clinically meaningful association between baseline or prospective A1c and wound healing in patients with DFUs,” concluded lead author Betiel Fesseha, MD, of the JHU division of endocrinology, diabetes and metabolism, and colleagues. “The paradoxical finding of accelerated wound healing and increase in hemoglobin A1c in participants with better baseline glycemic control requires confirmation in further studies.”

HbA1c refers to glycated hemoglobin, and is used to identify the average plasma glucose concentration over prolonged periods of time. For people without diabetes, the normal HbA1c range is 4-5.6%. HbA1c levels between 5.7% and 6.4% indicate increased risk of diabetes, and levels of 6.5% or higher indicate diabetes. The goal for diabetics is HbA1c levels lower than 7%, which should be retested every three months to determine target level control.

Related Links:
Johns Hopkins University


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.